Jilin Province Huinan Changlong Bio-pharmacy Co Ltd banner
J

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
HKEX:8049

Watchlist Manager
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
HKEX:8049
Watchlist
Price: 2.27 HKD -1.3% Market Closed
Market Cap: HK$1.3B

Wall Street
Price Targets

Price Targets Summary
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

There are no price targets for Jilin Province Huinan Changlong Bio-pharmacy Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd Competitors:
Price Targets

Revenue
Forecast

9% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
9% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Revenue forecast
is not available for
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

Operating Income
Forecast

9% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
9% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Operating Income forecast
is not available for
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

Net Income
Forecast

10% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
10% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Net Income forecast
is not available for
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Jilin Province Huinan Changlong Bio-pharmacy Co Ltd's stock price target?
Not Available

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd doesn't have any price targets made by Wall Street professionals.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett